Biopharmaceutical firms are restructuring Phase II clinical trial pipelines by incorporating predictive machine learning models to identify optimal trial sites and cohort profiles. Historical data shows up to 40% of trial delay costs stem from patient attrition.
Algorithmic Patient Matching
By analyzing real-world electronic health records, automated matchers select candidate pools with 30% higher retention probability. Early deployment reports demonstrate a 4.5-month reduction in overall trial execution windows.